MA44728A - PHARMACEUTICAL COMPOSITION CONSISTING OF A BETABLOQUANT, A CONVERSION ENZYME INHIBITOR AND AN ANTIHYPERTENSEUR OR AN NSAID - Google Patents

PHARMACEUTICAL COMPOSITION CONSISTING OF A BETABLOQUANT, A CONVERSION ENZYME INHIBITOR AND AN ANTIHYPERTENSEUR OR AN NSAID

Info

Publication number
MA44728A
MA44728A MA044728A MA44728A MA44728A MA 44728 A MA44728 A MA 44728A MA 044728 A MA044728 A MA 044728A MA 44728 A MA44728 A MA 44728A MA 44728 A MA44728 A MA 44728A
Authority
MA
Morocco
Prior art keywords
betabloquant
antihypertenseur
nsaid
pharmaceutical composition
composition consisting
Prior art date
Application number
MA044728A
Other languages
French (fr)
Inventor
Gilles Fonknechten
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MA44728A publication Critical patent/MA44728A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA044728A 2016-04-20 2017-04-19 PHARMACEUTICAL COMPOSITION CONSISTING OF A BETABLOQUANT, A CONVERSION ENZYME INHIBITOR AND AN ANTIHYPERTENSEUR OR AN NSAID MA44728A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1653502A FR3050380B1 (en) 2016-04-20 2016-04-20 PHARMACEUTICAL COMPOSITION COMPRISING A BETA-BLOCKER, A CONVERSION ENZYME INHIBITOR AND AN ANTIHYPERTENSOR OR NSAID.

Publications (1)

Publication Number Publication Date
MA44728A true MA44728A (en) 2019-02-27

Family

ID=56943614

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044728A MA44728A (en) 2016-04-20 2017-04-19 PHARMACEUTICAL COMPOSITION CONSISTING OF A BETABLOQUANT, A CONVERSION ENZYME INHIBITOR AND AN ANTIHYPERTENSEUR OR AN NSAID

Country Status (14)

Country Link
EP (1) EP3445342A1 (en)
KR (1) KR102267965B1 (en)
CN (1) CN109069438A (en)
BR (1) BR112018070968A2 (en)
EA (1) EA201892354A1 (en)
FR (1) FR3050380B1 (en)
GE (1) GEP20217310B (en)
MA (1) MA44728A (en)
PH (1) PH12018502155A1 (en)
RU (1) RU2756320C2 (en)
SG (2) SG10202009894PA (en)
TN (1) TN2018000344A1 (en)
UA (1) UA125511C2 (en)
WO (1) WO2017182754A1 (en)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2645710C2 (en) 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-aminopropanols, process for their manufacture and pharmaceutical preparation
FR2503155A2 (en) 1980-10-02 1982-10-08 Science Union & Cie NOVEL SUBSTITUTED IMINO DIACIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS AN ENZYME INHIBITOR
FR2620709B1 (en) 1987-09-17 1990-09-07 Adir PROCESS FOR THE INDUSTRIAL SYNTHESIS OF PERINDOPRIL AND ITS MAIN INTERMEDIATE SYNTHESIS
FR2807431B1 (en) 2000-04-06 2002-07-19 Adir NOVEL PROCESS FOR THE SYNTHESIS OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
FR2827860B1 (en) 2001-07-24 2004-12-10 Servier Lab NOVEL PROCESS FOR SYNTHESIS OF ACID DERIVATIVES (2S, 3AS, 7AS) -1 - [(S) -ALANYL] -OCTAHYDRO-1H-INDOLE-2-CARBOXYLINE AND APPLICATION TO THE SYNTHESIS OF PERINDOPRIL
AR036187A1 (en) 2001-07-24 2004-08-18 Adir A PROCESS FOR THE PREPARATION OF PERINDOPRIL, ANALOG COMPOUNDS AND ITS SALTS, INTERMEDIARY COMPOUND 2,5-DIOXO-OXAZOLIDINE AND PROCESS TO PREPARE A INTERMEDIARY
DE60220877T2 (en) 2002-01-30 2008-04-10 Les Laboratoires Servier Process for the preparation of high purity perindopril and intermediates useful in the synthesis
FR2838648B1 (en) 2002-04-18 2004-05-21 Servier Lab NEW PERINDOPRIL SALT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
EP1603558B1 (en) 2003-02-28 2008-05-21 Les Laboratoires Servier S.A. Process for preparation of perindopril and salts thereof
EP1403275B1 (en) 2003-02-28 2005-10-19 Les Laboratoires Servier Process for the synthesis of perindopril and its pharmaceutically acceptable salts
SI1321471T1 (en) 2003-03-12 2005-08-31 Servier Lab
DE60313391T2 (en) 2003-06-30 2008-01-17 Les Laboratoires Servier Process for the synthesis of perindopril and its pharmaceutically acceptable salts
DE60303101T2 (en) 2003-06-30 2006-09-28 Les Laboratoires Servier Process for the synthesis of perindopril and its pharmaceutically acceptable salts
CA2531279A1 (en) * 2003-07-28 2005-02-10 Dr. Reddy's Laboratories, Inc. Treatment and preventi0n of cardiovascular events
ATE337332T1 (en) 2003-07-31 2006-09-15 Servier Lab METHOD FOR THE SYNTHESIS OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
ATE338058T1 (en) 2003-07-31 2006-09-15 Servier Lab METHOD FOR THE SYNTHESIS OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
DK1371659T3 (en) 2003-08-29 2005-11-21 Servier Lab Process for the synthesis of perindopril and pharmaceutically acceptable salts thereof
DK1380591T3 (en) 2003-08-29 2006-01-23 Servier Lab Process for the synthesis of perindopril and pharmaceutically acceptable salts thereof
EP1380590B1 (en) 2003-08-29 2006-09-06 Les Laboratoires Servier Method for synthesis of perindopril and its pharmaceutically acceptable salts
ES2282586T3 (en) 2003-11-19 2007-10-16 Les Laboratoires Servier SYNTHESIS PROCEDURE OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS.
EP1422236B1 (en) 2003-11-19 2007-02-14 Les Laboratoires Servier Method for synthesis of perindopril and its pharmaceutically acceptable salts
ES2300555T3 (en) 2003-12-10 2008-06-16 Les Laboratoires Servier SYNTHESIS PROCEDURE OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS.
SI21800A (en) 2004-05-14 2005-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto New procedure of synthesis of perindopril
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
FR2894825B1 (en) 2005-12-21 2010-12-03 Servier Lab NOVEL ASSOCIATION OF SINUSAL IF CURRENT INHIBITOR AND CONVERSION ENZYME INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2897865B1 (en) 2006-02-28 2008-04-18 Servier Lab BETA CRYSTALLINE SHAPE OF PERINOPRIL ARGININE SALT, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2897866B1 (en) 2006-02-28 2008-04-18 Servier Lab ALPHA CRYSTALLINE FORM OF PERINOPRIL ARGININE SALT, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
CN101024082A (en) * 2007-04-06 2007-08-29 张士东 Compounded medicine for wholely preventing and treating cardio-cerebral blood vessel diseases and use thereof
AU2009263737B2 (en) 2008-06-24 2013-10-24 Mylan Laboratories Ltd. Novel polymorphic forms of Perindopril (L)-Arginine and process for the preparation thereof
HU230877B1 (en) 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stable pharmaceutical combination
NZ595127A (en) * 2009-02-11 2013-08-30 Cadila Pharmaceuticals Ltd Stable pharmaceutical composition for atherosclerosis
EP2424509A4 (en) * 2009-04-30 2012-11-07 Reddys Lab Ltd Dr Fixed dose drug combination formulations
FR2961105B1 (en) 2010-06-15 2013-02-08 Servier Lab USE OF THE ASSOCIATION OF A SINUSAL IF CURRENT INHIBITOR AND AN INHIBITOR OF THE ANGIOTENSIN CONVERSION ENZYME FOR THE TREATMENT OF CARDIAC INSUFFICIENCY
FR2985511B1 (en) 2012-01-05 2014-01-03 Servier Lab CRYSTALLINE DELTA FORM OF PERINOPRIL ARGININE SALT, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Also Published As

Publication number Publication date
KR20180132911A (en) 2018-12-12
WO2017182754A1 (en) 2017-10-26
CN109069438A (en) 2018-12-21
TN2018000344A1 (en) 2020-06-15
EP3445342A1 (en) 2019-02-27
SG11201808848SA (en) 2018-11-29
RU2018140193A3 (en) 2020-06-03
SG10202009894PA (en) 2020-11-27
BR112018070968A2 (en) 2019-01-29
GEP20217310B (en) 2021-11-10
FR3050380A1 (en) 2017-10-27
FR3050380B1 (en) 2020-07-10
EA201892354A1 (en) 2019-04-30
PH12018502155A1 (en) 2019-07-15
RU2018140193A (en) 2020-05-20
KR102267965B1 (en) 2021-06-21
UA125511C2 (en) 2022-04-13
RU2756320C2 (en) 2021-09-29

Similar Documents

Publication Publication Date Title
MA43709A (en) PHARMACEUTICAL COMPOSITION CONSISTING OF EMPAGLIFLOZIN AND ITS USES
MA46820A (en) PHARMACEUTICAL COMPOSITION INCLUDING BI-SPECIFIC ANTIBODY CONSTRUCTIONS
MA49043A (en) STABLE ANTIBODY FORMULATION
MA42971A (en) ANTI-PDL1 ANTIBODIES, ACTIVABLE ANTI-PLD1 ANTIBODIES, AND METHODS OF USE THEREOF
MA46525A (en) ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS
DK3331864T3 (en) 1,3,4-Oxadiazole derivative compounds as histone deacetylase-6 inhibitor, and the pharmaceutical composition comprising these
EP3524603A4 (en) Fgfr4 inhibitor, preparation method therefor and pharmaceutical use thereof
DK3328843T3 (en) 1,3,4-OXADIAZOLESULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE-6 INHIBITORS AND THE PHARMACEUTICAL COMPOSITION
MA47499A (en) ANTI-TAU BODIES AND THEIR METHODS OF USE
MA51747A (en) LOW PH PHARMACEUTICAL ANTIBODY FORMULATION
MA44659A (en) ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS
BR112017008666A2 (en) anti-fgfr2 / 3 antibodies and methods of use
MA46109A (en) HIGH CONCENTRATE, LOW VISCOSITY MASP-2 INHIBITOR ANTIBODY FORMULATIONS, KITS AND METHODS
MA44671A (en) ASSOCIATIONS AND METHODS INCLUDING A CAPSIDE SET INHIBITOR
MA39248B1 (en) Anti-jagged1 antibodies and methods of use thereof
MA54052A (en) ANTIBODY FORMULATION
MA54139A (en) ANTIBODY FORMULATION
FR3049465B1 (en) PREVENTIVE AND CURATIVE PHARMACEUTICAL COMPOSITION BASED ON PEROXOMETALLATE
EP3810143A4 (en) Nadph oxidase inhibitors, pharmaceutical composition comprising the same, and application thereof
MA47516A (en) PHARMACEUTICAL COMPOSITION
BR112017001888A2 (en) biological formulations for intravesical instillation
MA44286A (en) PHARMACEUTICAL FORMULATION OF CINEOL AND AMOXICILLIN
CO2019000596A2 (en) Combination of a bcl-2 inhibitor and an mcl1 inhibitor, uses and pharmaceutical compositions thereof
BR112017005993A2 (en) innovative peptide derivatives and uses thereof
MA44728A (en) PHARMACEUTICAL COMPOSITION CONSISTING OF A BETABLOQUANT, A CONVERSION ENZYME INHIBITOR AND AN ANTIHYPERTENSEUR OR AN NSAID